Community Practice Connections™: T-Cell Lymphoma Tumor Board: Application of Novel Agents for the Treatment of PTCL and CTCL

Release Date: February 16, 2021
Expiration Date: February 16, 2022

Activity Overview

T-cell lymphomas (TCLs) are a set of non-Hodgkin lymphomas (NHLs) that account for an estimated 5% to 20% of all NHL cases in Western countries. Common subtypes of peripheral T-cell lymphomas (PTCLs) include PTCL not otherwise specified, which is the most aggressive of all lymphoid neoplasms. There are over 10 subtypes of cutaneous T-cell lymphomas (CTCL) CTCL, with mycosis fungoides (MF) as the most common variant of CTCL, representing about 50% of all cases. The rapid pace and sheer volume of recent data has improved our understanding of TCL pathophysiology and has led to therapeutic advancements for the treatment of PTCL and CTCL focused on personalized management strategies.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the 62nd American Society of Hematology Annual Meeting & Exposition, held in December 2020. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with PTCL and CTCL, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Daiichi Sankyo, Inc., Seattle Genetics, and Takeda Oncology.

Target Audience

This activity is intended for medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with TCLs. Fellows, researchers, nurses, nurse practitioners, physician assistants, pharmacists, dermatologic oncologists, dermatologists, and other health care professionals interested in the treatment of patients with TCLs are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss specific disease subtypes of T-cell Lymphoma (TCL) and the role of molecular and phenotypic biomarkers for individualizing treatment decisions in patients with peripheral and cutaneous subtypes
• Review efficacy and safety data for currently available options for the treatment of patients with peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL)
• Plan strategies for proactively recognizing, monitoring, and managing adverse events associated with treatment of PTCL and CTCL in the frontline setting and beyond
• Review emerging novel therapies and strategies as well as the latest clinical trial data for the treatment of PTCL and CTCL

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Disclosures: Grant/Research Support: ADC Therapeutics, Affimed, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium /Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, Verastem; Consultant: ADC Therapeutics, C4 Therapeutics, Celgene, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, Seattle Genetics, Takeda, Trillium Therapeutics, Verastem, Vividion Therapeutics.

Disclosures: Consultant: Daichii-Sankyo; Speaker Bureau: Research to Practice, Curio.

Disclosures: Grant/Research Support: Roche, Takeda Pharmaceuticals; Consultant: EUSA Pharma US, Seattle Genetics, AbbVie.

Disclosures: Grant/Research Support: Bristol Myers Squibb, Celgene, Corvus Pharmaceuticals, Innate, Genentech, Roche, Verastem; Consultant: C4 Therapeutics, Daichii-Sankyo, Karyopharm, Kyowa Hakko Kirin, Ono.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.